NP-based Delivery System Development
The treatment of brain tumors presents unique challenges, primarily due to the protective nature of the blood-brain barrier (BBB). This highly selective barrier limits the passage of most therapeutic agents, making effective treatment of conditions like glioblastoma particularly difficult. Alfa Cytology specializes in the development and optimization of NP-based delivery systems tailored for brain tumor therapies.
Introduction to NP-Based Delivery Systems for Brain Tumors
Nanoparticle (NP) technology has emerged as a revolutionary approach in the treatment of brain tumors, addressing critical challenges posed by conventional therapies. The blood-brain barrier (BBB) presents a formidable obstacle in delivering therapeutic agents effectively to the central nervous system. This highly selective barrier restricts the passage of most drugs, leading to suboptimal treatment outcomes. NPs, due to their unique physicochemical properties, offer innovative solutions to enhance the delivery of chemotherapeutic agents, genes, and other therapeutic modalities directly to brain tumor sites.
Fig.1 Depicting the significance of 3D cancer models. (a) Drug screening. (b) Personalized medicine. (Park J.H., et al., 2024)
Recent studies highlight the versatility of various NP formulations, including polymeric, lipid-based, semiconductor, carbon-based, and ceramic nanoparticles. Each type possesses distinct mechanisms that facilitate crossing the BBB while ensuring targeted delivery to tumor cells. For instance, polymeric nanoparticles can be engineered for controlled release and sustained circulation, capitalizing on the enhanced permeability and retention (EPR) effect often seen in tumor tissues.
NP-Based Therapeutic Development for Brain Tumors
Patents published on nanoparticle-based approaches for the treatment of brain tumor.
| Patent no. |
Type of NPs |
Title of Invention |
Type of Study |
| KR102267519B1 |
Porus Silicon NPs |
Nanoparticles for drug delivery surface-modified with brain tumor cell targeting peptide preparation method thereof and use thereof |
In vivo |
| CN110859826A |
Biomimetic NPs |
Biomimetic drug-loaded nanoparticles targeting brain tumor and preparation method and application thereof |
In vivo |
| US10584144B2 |
RNA NPs |
RNA nanoparticles for brain tumor treatment |
In vivo |
| US11547729B2 |
Polymeric NPs |
Nanoparticle modification of human adipose-derived mesenchymal stem cells for treating brain cancer and other neurological |
In vivo |
| US2017326252A1 |
Viral NPs |
Nanoparticles for Delivery of Agents to Glioblastoma Tumors |
In vivo |
Our Services
Alfa Cytology specializes in the development and optimization of NP-based delivery systems tailored for brain tumor therapies. Our comprehensive services encompass the entire spectrum of NP design, synthesis, characterization, and preclinical evaluation, ensuring that our clients receive cutting-edge solutions aligned with their therapeutic goals.
NP Design and Synthesis
Utilizing a variety of materials—ranging from biodegradable polymers to lipid carriers—we develop nanoparticles that are specifically designed to encapsulate active pharmaceutical ingredients (APIs) and facilitate targeted delivery.
Characterization and Optimization
At Alfa Cytology, we utilize sophisticated techniques such as dynamic light scattering (DLS), transmission electron microscopy (TEM), and high-performance liquid chromatography (HPLC) to assess the size, morphology, and drug loading efficiency of our nanoparticles.
Preclinical Evaluation
Our preclinical services include comprehensive in vitro and in vivo studies to evaluate the pharmacokinetics, biodistribution, and therapeutic efficacy of NP formulations. By employing relevant animal models, we assess the ability of our nanoparticles to cross the BBB and their subsequent impact on tumor growth and survival rates.
Contact Us
For inquiries about our NP-based delivery system development services or to discuss potential collaborations, please contact Alfa Cytology. Our dedicated team of experts is ready to assist you in advancing your projects and achieving your therapeutic objectives.
Reference
- Ahamed, Jisan, et al. (2023) "Recent advances in nanoparticle-based approaches for the treatment of brain tumors: Opportunities and challenges." [J]. European Polymer Journal. 193: 112111.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
